Paone, JF, et al. Serum UDP-galactosyl transferase as a potential biomarker for breast carcinoma. Journal of Surgical Oncology
1980; 15: 59–66.
Lyons, TJ, Basu, A. Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers. Translational Research
2012; 159: 303–312.
Prensner, JR, et al. Beyond PSA: the next generation of prostate cancer biomarkers. Science Translational Medicine
2012; 4: 127rv3.
James, CR, et al.
BRCA1, a potential predictive biomarker in the treatment of breast cancer. The Oncologist
2007; 12: 142–150.
Boone, CW, Kelloff, GJ. Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention. Journal of Cellular Biochemistry Supplement
1993; 17: F37–F48.
Price, ND, et al. A wellness study of 108 individuals using personal, dense, dynamic data clouds. Nature Biotechnology
2017; 35: 747–756.
Poste, G, Compton, CC, Barker, AD. The National Biomarker Development Alliance: confronting the poor productivity of biomarker research and development. Expert Review of Molecular Diagnostics
2015; 15: 211–218.
FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring, MD: Food and Drug Administration, 2016. Co-published by National Institutes of Health (US), Bethesda, MD. (https://www.ncbi.nlm.nih.gov/books/NBK326791)
Ross, JS. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. Drug News & Perspectives
2009; 22: 93–106.
Goossens, N, et al. Cancer biomarker discovery and validation. Translational Cancer Research
2015; 4: 256–269.
Ferlini, A, Scotton, C, Novelli, G. Biomarkers in rare diseases. Public Health Genomics
2013; 16: 313–321.
Ferreira, D, et al. Improving CSF biomarkers’ performance for predicting progression from mild cognitive impairment to Alzheimer’s disease by considering different confounding factors: a meta-analysis. Frontiers in Aging Neuroscience
2014; 6: 287.
Kreitmair, KV, Cho, MK, Magnus, DC. Consent and engagement, security, and authentic living using wearable and mobile health technology. Nature Biotechnology
2017; 35: 617–620.
Bouallègue, B, et al. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer’s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database. Alzheimer’s Research & Therapy
2017; 9: 32.
Weiner, MW, et al. The Alzheimer’s disease neuroimaging initiative: a review of papers published since its inception. Alzheimer’s & Dementia
2013; 9: e111–e194.
Kawas, C, et al. Age-specific incidence rates of Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology
2000; 54: 2072–2077.
Zhan, A, et al. High frequency remote monitoring of Parkinson’s disease via smartphone: platform overview and medication response detection. 2016. Epub ahead of print, arXiv: 1601.00960.
Rentz, DM, et al. The feasibility of at-home iPad cognitive testing for use in clinical trials. Journal of Prevention of Alzheimer’s Disease
2016; 3: 8–12.
Adams, JL, et al. Multiple wearable sensors in Parkinson and Huntington disease individuals: a pilot study in clinic and at home. Digital Biomarkers
2017; 1: 52–63.
Wortley, D, An, JY, Nigg, CR. Wearable technologies, health and well-being: a case review. Digital Medicine
2017; 3: 11–17.
Giggins, OM, Clay, I, Walsh, L. Physical activity monitoring in patients with neurological disorders: a review of novel body-worn devices. Digital Biomarkers
2017; 1: 14–42.
Wortley, D. The future of digital medicine in the aging society. Digital Medicine
2016; 2: 43–45.
Dorsey, ER, Marks, WJ Jr. Verily and its approach to digital biomarkers. Digital Biomarkers
2017; 1: 96–99.
Wang, T, Azad, T, Rajan, R. The emerging influence of digital biomarkers on healthcare [Internet], 2016 [cited Jan 16, 2018]. (https://rockhealth.com/reports/)
Wortley, DJ. The consumerization of digital medicine. Digital Medicine
2016; 2: 135–139.
Dorsey, ER. A digital journal for a digital era. Digital Biomarkers
2017; 1: 1–3.
Rodarte, C. Pharmaceutical perspective: how digital biomarkers and contextual data will enable therapeutic environments. Digital Biomarkers
2017; 1: 73–81.
Heldman, DA, et al. Telehealth management of Parkinson’s disease using wearable sensors: an exploratory study. Digital Biomarkers
2017; 1: 43–51.
Tamborlane, WV, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. New England Journal of Medicine
2008; 359: 1464–1476.
Lind, M, Polonsky, W, Hirsch, IB. Continuous glucose monitoring vs. conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. Journal of American Medical Association
2017; 317: 379–387.
Doyle, FJ III, et al. Closed-loop artificial pancreas systems: engineering the algorithms. Diabetes Care
2014; 37: 1191–1197.
Lee, JM, Hirschfeld, E, Wedding, J. A patient-designed do-it-yourself mobile technology system for diabetes: promise and challenges for a new era in medicine. Journal of American Medical Association
2016; 315: 1447–1448.
Bergenstal, RM, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type-1 diabetes. Journal of American Medical Association
2016; 316: 1407–1408.
Tamura, T, et al. Wearable photoplethysmographic sensors—past and present. Electronics
2014; 3: 282–302.
Allen, J. Photoplethysmography and its application in clinical physiological measurement. Physiological Measurement
2007; 28: R1.
Kinter, M, et al. Measurement of cholesterol in serum by gas chromatography/mass spectrometry at moderate mass resolution, with a nonendogenous cholesterol isomer as internal standard. Clinical Chemistry
1988; 34: 531–534.
Silva de Lima, AL, et al. Large-scale wearable sensor deployment in Parkinson’s patients: the Parkinson@ Home Study Protocol. JMIR Research Protocols
2016; 5: e172.
Steinberg, D, Horwitz, G, Zohar, D. Building a business model in digital medicine. Nature Biotechnology
2015; 33: 910–920.
Knuston, KL, Ryden, AM, Mander, BA. Role of sleep duration and quality in the risk and severity of type 2 diabetes mellitus. Archives of Internal Medicine
2006; 166: 1768–1774.
Riddell, MC, et al. Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol
2017; 5: 377–390.
Yong, PL, Saunders, RS, Olsen, L.
The Healthcare Imperative: Lowering Costs and Improving Outcomes: Workshop Series Summary
. Washington, DC: National Academies Press, 2010; PMID: 21595114.
Marshall, A. Wanted: biotech for an aging population. Nature Biotechnology
2017; 35: 597.
Li, X, et al. Digital health: tracking physiomes and activity using wearable biosensors reveals useful health-related information. PLoS Biology
2017; 15: e2001402.
Torous, J, Rodriguez, J, Powell, A. The new digital divide for digital biomarkers. Digital Biomarkers
2017; 1: 87–91.
Carrigan, P, Krahn, T. Impact of biomarkers on personalized medicine. Handbook of Experimental Pharmacology
2016; 232: 285–311.
Hood, L, Price, ND. Promoting wellness and demystifying disease: the 100K wellness project. Clinical Omics
2014; 1: 20–23.
Case, MA, et al. Accuracy of smartphone applications and wearable devices for tracking physical activity data. Journal of American Medical Association
2015; 313: 625–626.
Malinowski, JR, et al. Genetic variants associated with serum thyroid stimulating hormone (TSH) levels in European Americans and African Americans from the eMERGE network. PLoS One
2014; 9: e111301.
Stockigt, J. Assessment of thyroid function: towards an integrated laboratory – clinical approach. Clinical Biochemist Review
2003; 24: 109–122.
Collins, FS, Varmus, H. A new initiative on precision medicine. New England Journal of Medicine
2015; 372: 793–795.
Dorsey, ER, et al. The first frontier: digital biomarkers for neurodegenerative disorders. Digital Biomarkers
2017; 1: 6–13.